| P50 | author | Anna Minarini | Q57078501 |
| P2093 | author name string | Carlo Melchiorre | |
| | Michela Rosini | |
| | Elena Simoni | |
| P2860 | cites work | Alzheimer's Disease | Q22248111 |
| | Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond | Q22251042 |
| | Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease | Q27025207 |
| | Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer | Q28207603 |
| | The cholinergic hypothesis of geriatric memory dysfunction | Q28277644 |
| | Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study | Q28287733 |
| | Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid-β-mediated Alzheimer's disease-associated pathogenesis in vitro and in vivo | Q28481239 |
| | On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis | Q33421837 |
| | Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse | Q34007194 |
| | The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine | Q34121123 |
| | Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors | Q34185133 |
| | Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment | Q34227976 |
| | Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade | Q34536179 |
| | Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush | Q46498424 |
| | Neuroprotective activities of carvedilol and a hydroxylated derivative: role of membrane biophysical interactions | Q48286399 |
| | Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease | Q48351188 |
| | Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity | Q48415128 |
| | Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease | Q48913512 |
| | Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice. | Q50775755 |
| | The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon. | Q50859830 |
| | Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. | Q53224731 |
| | A small molecule targeting the multifactorial nature of Alzheimer's disease. | Q53285864 |
| | Therapies for Alzheimer's disease. | Q53287138 |
| | Tacrine(2)-ferulic acid, a novel multifunctional dimer, attenuates 6-hydroxydopamine-induced apoptosis in PC12 cells by activating Akt pathway. | Q54557691 |
| | Alzheimer's disease | Q55880664 |
| | Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer | Q56992084 |
| | Dimebon in Alzheimer's disease: old drug for new indication | Q57526213 |
| | Tacrine-6-Ferulic Acid, a Novel Multifunctional Dimer Against Alzheimer's Disease, Prevents Oxidative Stress-Induced Neuronal Death Through Activating Nrf2/ARE/HO-1 Pathway in HT22 Cells | Q61739382 |
| | Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons | Q74273168 |
| | Pharmacology. The puzzling rise and fall of a dark-horse Alzheimer's drug | Q83180109 |
| | Insight into amyloid structure using chemical probes | Q34990429 |
| | The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies | Q35668146 |
| | Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology | Q36134380 |
| | Designed multiple ligands. An emerging drug discovery paradigm | Q36284452 |
| | Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease | Q36523691 |
| | Rationale for combination therapy with galantamine and memantine in Alzheimer's disease | Q36523696 |
| | 100 years and counting: prospects for defeating Alzheimer's disease | Q36643419 |
| | Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors | Q36653733 |
| | Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity. | Q36713096 |
| | Fragments, network biology and designing multiple ligands | Q36727203 |
| | Multi-target-directed ligands to combat neurodegenerative diseases | Q37052982 |
| | From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease | Q37265047 |
| | Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. | Q37294285 |
| | Alzheimer's disease: new approaches to drug discovery | Q37495202 |
| | Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential | Q37548763 |
| | Tacrine derivatives and Alzheimer's disease. | Q37719563 |
| | Strategies for the inhibition of protein aggregation in human diseases | Q37733418 |
| | Alzheimer's disease: strategies for disease modification | Q37739810 |
| | Combination therapy for Alzheimer's disease | Q37896602 |
| | Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. | Q37906464 |
| | Multitarget-directed ligands: innovative chemical probes and therapeutic tools against Alzheimer's disease | Q37951068 |
| | Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections | Q38014513 |
| | Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease | Q38056559 |
| | Polypharmacology in a single drug: multitarget drugs | Q38081536 |
| | Polypharmacology - foe or friend? | Q38126927 |
| | Dual inhibitors of β-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates | Q38127824 |
| | Multifunctional tacrine derivatives in Alzheimer's disease | Q38127827 |
| | Excitatory amino acids and Alzheimer's disease | Q38301056 |
| | Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease | Q39472542 |
| | Rational approach to discover multipotent anti-Alzheimer drugs. | Q40469271 |
| | Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation | Q40925045 |
| | Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. | Q42487590 |
| | Simultaneous release of glutamate and acetylcholine from single magnocellular "cholinergic" basal forebrain neurons. | Q42490283 |
| | NR2B-containing NMDA receptors expression and their relationship to apoptosis in hippocampus of Alzheimer's disease-like rats | Q42502548 |
| | Synthesis of monomeric derivatives to probe memoquin's bivalent interactions. | Q42725421 |
| | Bis(7)-tacrine derivatives as multitarget-directed ligands: Focus on anticholinesterase and antiamyloid activities | Q43058871 |
| | From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes | Q44335899 |
| | Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine | Q44348644 |
| | Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 3. Effect of replacing the inner polymethylene chain with cyclic moieties | Q45179916 |
| | Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors | Q46383054 |
| P433 | issue | 10 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 1914-1923 | |
| P577 | publication date | 2014-02-04 | |
| P1433 | published in | Neurochemical Research | Q15716728 |
| P1476 | title | Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces | |
| P478 | volume | 39 | |